Creative Med Technology Hldgs Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Creative Med Technology Hldgs has an operating margin of -52216.9%, meaning the company retains $-52217 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -62445.9% the prior year.
Creative Med Technology Hldgs's revenue surged 22.2% year-over-year to $11K, reflecting rapid business expansion. This strong growth earns a score of 92/100.
Creative Med Technology Hldgs carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 18.73, Creative Med Technology Hldgs holds $18.73 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Creative Med Technology Hldgs passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Creative Med Technology Hldgs generates $0.97 in operating cash flow (-$5.3M OCF vs -$5.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Creative Med Technology Hldgs (CELZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Creative Med Technology Hldgs generated $11K in revenue in fiscal year 2024. This represents an increase of 22.2% from the prior year.
Creative Med Technology Hldgs's EBITDA was -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.2% from the prior year.
Creative Med Technology Hldgs reported -$5.5M in net income in fiscal year 2024. This represents a decrease of 3.9% from the prior year.
Creative Med Technology Hldgs earned $-3.71 per diluted share (EPS) in fiscal year 2024. This represents an increase of 1.3% from the prior year.
Creative Med Technology Hldgs held $5.9M in cash against $0 in long-term debt as of fiscal year 2024.
Creative Med Technology Hldgs had 2M shares outstanding in fiscal year 2024. This represents an increase of 27.3% from the prior year.
Creative Med Technology Hldgs's gross margin was 60.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.0 percentage points from the prior year.
Creative Med Technology Hldgs's operating margin was -52216.9% in fiscal year 2024, reflecting core business profitability. This is up 10229.0 percentage points from the prior year.
Creative Med Technology Hldgs's net profit margin was -49940.7% in fiscal year 2024, showing the share of revenue converted to profit. This is up 8799.0 percentage points from the prior year.
Creative Med Technology Hldgs invested $2.4M in research and development in fiscal year 2024. This represents an increase of 21.8% from the prior year.
Creative Med Technology Hldgs spent $175K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 35.4% from the prior year.
CELZ Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | $3K0.0% | $3K-62.5% | $8K | $0-100.0% | $3K-50.0% | $6K |
| Cost of Revenue | $0 | $0-100.0% | $1K0.0% | $1K-62.5% | $3K | $0-100.0% | $1K-50.0% | $2K |
| Gross Profit | $0 | $0-100.0% | $2K0.0% | $2K-62.5% | $5K | $0-100.0% | $2K-50.0% | $4K |
| R&D Expenses | $465K-7.2% | $501K-32.6% | $743K+57.5% | $472K-49.0% | $925K+118.9% | $422K+20.9% | $349K-64.8% | $993K |
| SG&A Expenses | $777K+6.2% | $732K-17.7% | $888K-36.2% | $1.4M+106.0% | $676K+0.7% | $671K-52.0% | $1.4M+163.4% | $531K |
| Operating Income | -$1.3M-0.8% | -$1.3M+23.9% | -$1.7M+11.9% | -$1.9M-16.0% | -$1.6M-44.7% | -$1.1M+36.6% | -$1.8M-14.8% | -$1.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1.2M-0.2% | -$1.2M+24.7% | -$1.6M+11.6% | -$1.9M-19.0% | -$1.6M-49.6% | -$1.0M+38.0% | -$1.7M-15.4% | -$1.5M |
| EPS (Diluted) | $-0.480.0% | $-0.48-157.8% | $0.83+132.2% | $-2.58-132.4% | $-1.11-252.1% | $0.73 | N/A | N/A |
CELZ Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.9M-17.6% | $7.1M-14.9% | $8.3M+25.2% | $6.7M-16.5% | $8.0M-16.9% | $9.6M-10.2% | $10.7M-14.4% | $12.5M |
| Current Assets | $5.4M-18.4% | $6.6M-15.4% | $7.8M+27.9% | $6.1M-19.3% | $7.6M-17.4% | $9.2M-10.4% | $10.3M-14.7% | $12.0M |
| Cash & Equivalents | $5.4M-17.9% | $6.5M-15.0% | $7.7M+29.7% | $5.9M-20.5% | $7.5M-17.1% | $9.0M+159.8% | $3.5M-23.1% | $4.5M |
| Inventory | $9940.0% | $9940.0% | $994-54.7% | $2K-35.4% | $3K-48.5% | $7K0.0% | $7K-15.4% | $8K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $261K-5.9% | $278K-3.1% | $286K-12.6% | $328K-12.9% | $376K-3.8% | $391K+5.3% | $371K-11.8% | $421K |
| Current Liabilities | $261K-5.9% | $278K-3.1% | $286K-12.6% | $328K-12.9% | $376K-3.8% | $391K+5.3% | $371K-11.8% | $421K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.6M-18.1% | $6.8M-15.3% | $8.1M+27.1% | $6.3M-16.7% | $7.6M-17.5% | $9.2M-10.8% | $10.3M-14.5% | $12.1M |
| Retained Earnings | -$68.7M-1.8% | -$67.5M-1.9% | -$66.2M-2.5% | -$64.6M-4.7% | -$61.7M-2.6% | -$60.1M-1.8% | -$59.1M-2.9% | -$57.4M |
CELZ Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M-0.9% | -$1.2M+27.2% | -$1.6M+18.4% | -$1.9M-32.7% | -$1.5M-63.8% | -$897K+52.7% | -$1.9M-45.3% | -$1.3M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0-100.0% | $6.5M+598.2% | $934K-53.6% | $2.0M |
| Financing Cash Flow | $0 | $0-100.0% | $3.4M+105.8% | $1.6M+2546.0% | -$67K+19.5% | -$83K-4.6% | -$79K+58.7% | -$192K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0-100.0% | $10K | $0-100.0% | $67K-19.4% | $83K+4.6% | $79K-58.7% | $192K |
CELZ Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 60.0%0.0pp | 60.0%0.0pp | 60.0% | N/A | 60.0%0.0pp | 60.0% |
| Operating Margin | N/A | N/A | -55349.3%+7508.5pp | -62857.8%-42541.5pp | -20316.3% | N/A | -59061.3%-33341.6pp | -25719.8% |
| Net Margin | N/A | N/A | -54603.2%+7199.2pp | -61802.5%-42330.9pp | -19471.6% | N/A | -55952.5%-31719.9pp | -24232.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -21.1%-3.8pp | -17.4%+2.3pp | -19.6%+8.2pp | -27.8%-8.3pp | -19.5%-8.7pp | -10.8%+4.8pp | -15.7%-4.1pp | -11.6% |
| Current Ratio | 20.71-3.2 | 23.89-3.5 | 27.39+8.7 | 18.73-1.5 | 20.21-3.3 | 23.54-4.1 | 27.66-0.9 | 28.60 |
| Debt-to-Equity | 0.050.0 | 0.040.0 | 0.04-0.0 | 0.050.0 | 0.050.0 | 0.040.0 | 0.040.0 | 0.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Creative Med Technology Hldgs's annual revenue?
Creative Med Technology Hldgs (CELZ) reported $11K in total revenue for fiscal year 2024. This represents a 22.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Creative Med Technology Hldgs's revenue growing?
Creative Med Technology Hldgs (CELZ) revenue grew by 22.2% year-over-year, from $9K to $11K in fiscal year 2024.
Is Creative Med Technology Hldgs profitable?
No, Creative Med Technology Hldgs (CELZ) reported a net income of -$5.5M in fiscal year 2024, with a net profit margin of -49940.7%.
What is Creative Med Technology Hldgs's earnings per share (EPS)?
Creative Med Technology Hldgs (CELZ) reported diluted earnings per share of $-3.71 for fiscal year 2024. This represents a 1.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Creative Med Technology Hldgs's EBITDA?
Creative Med Technology Hldgs (CELZ) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Creative Med Technology Hldgs's gross margin?
Creative Med Technology Hldgs (CELZ) had a gross margin of 60.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Creative Med Technology Hldgs's operating margin?
Creative Med Technology Hldgs (CELZ) had an operating margin of -52216.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Creative Med Technology Hldgs's net profit margin?
Creative Med Technology Hldgs (CELZ) had a net profit margin of -49940.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Creative Med Technology Hldgs's operating cash flow?
Creative Med Technology Hldgs (CELZ) generated -$5.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Creative Med Technology Hldgs's total assets?
Creative Med Technology Hldgs (CELZ) had $6.7M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Creative Med Technology Hldgs spend on research and development?
Creative Med Technology Hldgs (CELZ) invested $2.4M in research and development during fiscal year 2024.
Does Creative Med Technology Hldgs buy back shares?
Yes, Creative Med Technology Hldgs (CELZ) spent $175K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Creative Med Technology Hldgs have outstanding?
Creative Med Technology Hldgs (CELZ) had 2M shares outstanding as of fiscal year 2024.
What is Creative Med Technology Hldgs's current ratio?
Creative Med Technology Hldgs (CELZ) had a current ratio of 18.73 as of fiscal year 2024, which is generally considered healthy.
What is Creative Med Technology Hldgs's debt-to-equity ratio?
Creative Med Technology Hldgs (CELZ) had a debt-to-equity ratio of 0.05 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Creative Med Technology Hldgs's return on assets (ROA)?
Creative Med Technology Hldgs (CELZ) had a return on assets of -82.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Creative Med Technology Hldgs's cash runway?
Based on fiscal year 2024 data, Creative Med Technology Hldgs (CELZ) had $5.9M in cash against an annual operating cash burn of $5.3M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Creative Med Technology Hldgs's Piotroski F-Score?
Creative Med Technology Hldgs (CELZ) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Creative Med Technology Hldgs's earnings high quality?
Creative Med Technology Hldgs (CELZ) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Creative Med Technology Hldgs?
Creative Med Technology Hldgs (CELZ) scores 73 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.